Eagle Pharmaceuticals: Q4 Earnings Insights

Eagle Pharmaceuticals EGRX reported its Q4 earnings results on Monday, March 7, 2022 at 06:50 AM.

Here's what investors need to know about the announcement.

Eagle Pharmaceuticals missed estimated earnings by 9.57%, reporting an EPS of $0.85 versus an estimate of $0.94.

Revenue was down $7.60 million from the same period last year.

Last quarter the company missed on EPS by $0.27 which was followed by a 0.6% increase in the share price the next day.

Here's a look at Eagle Pharmaceuticals's past performance:

Quarter	Q3 2021	Q2 2021	Q1 2021	Q4 2020
EPS Estimate	0.83	0.80	0.65	-0.17
EPS Actual	0.56	0.93	0.24	0.96
Revenue Estimate	46.40M	45.86M	45.41M	53.16M
Revenue Actual	39.85M	48.12M	41.25M	49.92M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga's automated content engine and reviewed by an editor.